|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 37.00 USD | -0.51% |
|
+18.14% | +35.93% |
| 09-21 | BofA Securities Adjusts Agios Pharmaceuticals Price Target to $50 From $46, Maintains Buy Rating | MT |
| 07-30 | Agios Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026 |
Company Valuation: Agios Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,785 | 1,543 | 1,245 | 1,874 | 1,587 | 2,209 | - | - |
| Change | - | -13.57% | -19.32% | 50.56% | -15.3% | 39.17% | - | - |
| Enterprise Value (EV) 1 | 1,582 | 1,421 | 1,215 | 1,874 | 732.9 | 2,076 | 2,191 | 2,008 |
| Change | - | -10.21% | -14.49% | 54.29% | -60.89% | 183.21% | 5.55% | -8.33% |
| P/E | 1.24x | -6.64x | -3.52x | 2.82x | -3.82x | -6.42x | -9.83x | -20.9x |
| PBR | 1.54x | 1.4x | 1.53x | 1.22x | 1.33x | 2.4x | 3x | 3.31x |
| PEG | - | 0x | -0.1x | -0x | 0x | 0.3x | 0.3x | 0.4x |
| Capitalization / Revenue | - | 108x | 46.4x | 51.3x | 29.4x | 12.5x | 6.4x | 4.29x |
| EV / Revenue | - | 99.8x | 45.3x | 51.3x | 13.6x | 11.7x | 6.34x | 3.9x |
| EV / EBITDA | -4.29x | -3.73x | -3.16x | -4.46x | -1.57x | -5.48x | -8.81x | -18.7x |
| EV / EBIT | -4.18x | -3.65x | -3.1x | -4.4x | -1.55x | -5.44x | -8.01x | -13.5x |
| EV / FCF | -3.83x | -4.52x | -4.09x | -4.79x | -1.94x | -14.3x | -18.7x | 64.1x |
| FCF Yield | -26.1% | -22.1% | -24.5% | -20.9% | -51.5% | -7% | -5.34% | 1.56% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 26.55 | -4.23 | -6.33 | 11.64 | -7.12 | -5.764 | -3.766 | -1.766 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 14.24 | 26.82 | 36.5 | 54.03 | 176.7 | 345.4 | 515.1 |
| EBITDA 1 | -369.2 | -380.5 | -384.9 | -420.1 | -467 | -378.6 | -248.7 | -107.4 |
| EBIT 1 | -378.4 | -389 | -391.5 | -425.7 | -472.1 | -381.7 | -273.6 | -149 |
| Net income 1 | 1,605 | -231.8 | -352.1 | 673.7 | -412.8 | -343.1 | -234.4 | -109.8 |
| Net Debt 1 | -203.1 | -122.3 | -30.06 | - | -854.4 | -133.4 | -18.27 | -200.7 |
| Reference price 2 | 32.87 | 28.08 | 22.27 | 32.86 | 27.22 | 37.00 | 37.00 | 37.00 |
| Nbr of stocks (in thousands) | 54,308 | 54,945 | 55,891 | 57,030 | 58,314 | 59,702 | - | - |
| Announcement Date | 2/24/22 | 2/23/23 | 2/15/24 | 2/13/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.42x | 11.75x | -5.48x | -.--% | 2.21B | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 23.45x | 24.99x | 13.56x | 0.29% | 38.53B | |
| Weighted average by Cap. | 26.53x | 25.25x | 15.78x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AGIO Stock
- Valuation Agios Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
